Jean Jacques Bienaime Biomarin Pharmaceutical Inc (BMRN) insider trading activity

Jean Jacques Bienaime is Director of BIOMARIN PHARMACEUTICAL INC. Currently has a direct ownership of 473,792 shares of BMRN, which is worth approximately $30.3 Million. The most recent transaction as insider was on Apr 18, 2022, when has been sold 20,000 shares (Common Stock) at a price of $81.91 per share, resulting in proceeds of $1,638,200. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 474K

0% 3M change

12.91% 12M change

Total Value Held $30.3 Million

JEAN JACQUES BIENAIME Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 18 2022	SELL Open market or private sale	$1,638,200 $81.91 p/Share	20,000 Reduced 5.63%	334,983 Common Stock
Apr 18 2022	BUY Exercise of conversion of derivative security	$749,200 $37.46 p/Share	20,000 Added 5.33%	354,983 Common Stock
Apr 14 2022	SELL Open market or private sale	$836,600 $83.66 p/Share	10,000 Reduced 2.9%	334,983 Common Stock
Apr 14 2022	BUY Exercise of conversion of derivative security	$374,600 $37.46 p/Share	10,000 Added 2.82%	344,983 Common Stock
Mar 16 2022	SELL Payment of exercise price or tax liability	$448,803 $80.72 p/Share	5,560 Reduced 1.63%	334,983 Common Stock
Mar 15 2022	SELL Payment of exercise price or tax liability	$2,998,210 $78.27 p/Share	38,306 Reduced 10.11%	340,543 Common Stock
Mar 15 2022	BUY Grant, award, or other acquisition	-	40,280 Added 9.61%	378,849 Common Stock
Mar 11 2022	SELL Open market or private sale	$1,167,150 $77.81 p/Share	15,000 Reduced 4.24%	338,569 Common Stock
Mar 11 2022	BUY Exercise of conversion of derivative security	$561,900 $37.46 p/Share	15,000 Added 4.07%	353,569 Common Stock
Mar 10 2022	SELL Open market or private sale	$1,163,550 $77.57 p/Share	15,000 Reduced 4.24%	338,569 Common Stock
Mar 10 2022	BUY Exercise of conversion of derivative security	$561,900 $37.46 p/Share	15,000 Added 4.07%	353,569 Common Stock
Mar 08 2022	BUY Grant, award, or other acquisition	-	34,780 Added 9.32%	338,569 Common Stock
Jan 13 2022	SELL Open market or private sale	$439,300 $87.86 p/Share	5,000 Reduced 1.62%	303,789 Common Stock
Jan 13 2022	BUY Exercise of conversion of derivative security	$187,300 $37.46 p/Share	5,000 Added 1.59%	308,789 Common Stock
Jan 12 2022	SELL Open market or private sale	$445,000 $89.0 p/Share	5,000 Reduced 1.62%	303,789 Common Stock
Jan 12 2022	BUY Exercise of conversion of derivative security	$187,300 $37.46 p/Share	5,000 Added 1.59%	308,789 Common Stock
Dec 21 2021	BUY Small Acquisition	$8,922 $89.22 p/Share	100 Added 0.03%	303,789 Common Stock
Dec 16 2021	SELL Open market or private sale	$508,080 $84.68 p/Share	6,000 Reduced 1.94%	303,689 Common Stock
Dec 16 2021	BUY Exercise of conversion of derivative security	$224,760 $37.46 p/Share	6,000 Added 1.9%	309,689 Common Stock
Dec 15 2021	SELL Open market or private sale	$496,260 $82.71 p/Share	6,000 Reduced 1.94%	303,689 Common Stock
Dec 15 2021	BUY Exercise of conversion of derivative security	$224,760 $37.46 p/Share	6,000 Added 1.9%	309,689 Common Stock
Dec 10 2021	SELL Bona fide gift	-	700 Reduced 0.23%	303,689 Common Stock
Dec 01 2021	SELL Open market or private sale	$130,830 $87.22 p/Share	1,500 Reduced 0.49%	304,389 Common Stock
Oct 20 2021	BUY Exercise of conversion of derivative security	$37,460 $37.46 p/Share	1,000 Added 0.33%	305,839 Common Stock
Sep 09 2021	BUY Small Acquisition	$3,938 $78.77 p/Share	50 Added 0.02%	305,889 Common Stock

Also insider at

INCY

INCYTE CORP Healthcare

Director

KROS

Keros Therapeutics, Inc. Healthcare

IMNM

Immunome Inc. Healthcare

JJB